Hi [[ session.user.profile.firstName ]]

PMGroup

  • Date
  • Rating
  • Views
  • Communicating innovation to payers and policy makers Communicating innovation to payers and policy makers Dominic Tyer Recorded: Nov 28 2016 36 mins
    Involving public affairs early during the development and commercialisation process of a new asset is critical to success when demonstrating value to payers and policy makers.

    But how can the pharmaceutical industry best support these key stakeholders and the wider healthcare community when it comes to realising the potential of innovation?

    On Monday 28 November, Cello Health, in association with PMGroup, will host a free webinar on how to reach the tipping point of stakeholder engagement.

    The webinar will review the ‘total quality management’ model and deliver key learnings, tools and tactics from aligned and well-evidenced programmes that have followed this model.
  • Immuno-oncology's evolution: implications for pharma market researchers Immuno-oncology's evolution: implications for pharma market researchers Dominic Tyer Recorded: Nov 17 2016 48 mins
    Immuno-oncology therapies that harness the body’s own defences to fight tumours are widely acknowledged as the new frontier in cancer treatment, but until recently only a few products had reached the market for a limited number of indications.

    Over the past 12 months several new products have been approved for a wider range of tumour types and with pipelines boasting numerous other products in the area, competition looks set to hot up.

    On November 17 Research Partnership, in association with PMGroup, will host a free webinar which will explore the key features of the immuno-oncology market and the critical success factors for remaining competitive.

    I would like to invite you to register for the webinar - either to watch it live on the day or for access to a recorded version.
  • Scale & Strategy: Essential tools for transforming the commercial model Scale & Strategy: Essential tools for transforming the commercial model Dominic Tyer Recorded: Nov 9 2016 42 mins
    Most life sciences companies know they need to move their multichannel marketing forward, but that requires managing a greater volume of tactics that need to be developed, approved, implemented, and measured.

    And of course, those tactics must reflect how their target audiences engage in content – such as the 65% of healthcare professionals who say they prefer clinical summaries.

    To truly transform the commercial model, companies must have a strategic blueprint that combines business objectives with brand goals to determine the appropriate resource levels and channel attribution.

    On November 9 Aptus Health, in association with PMGroup, will explore three essential ingredients for transforming the commercial model and driving success:

    • Learn how to deploy multichannel marketing at scale through integrated campaigns that reach millions of HCPs across specialties, languages, and markets

    • Gain insights into your target HCPs’ behaviours - and how to leverage those insights to make your campaigns more effective

    • Explore results from a recent survey of European HCPs revealing their preferences for the types of online medical education, as well as the resources they find most helpful in their daily practice
  • Driving adoption of Commercial Analytic solutions Driving adoption of Commercial Analytic solutions Dominic Tyer Recorded: Oct 25 2016 50 mins
    Commercial analytic solutions are becoming more and more common within the Pharma industry. Companies are spending millions implementing tools which are aimed at helping users identify opportunities to improve the bottom line, segment customers, track multichannel campaign success and meet a myriad of other objectives. Despite all the 'perceived' value these tools can add, they remain largely unused. Excuses for the lack of adoption are varied but can generally be classified into one of three areas - they are either too complex, it isn't convenient to use or it just doesn't deliver on the value promised. These issues are compounded by the fact that they are generally only identified when the solution has been deployed and expected to be used. By ensuring that these issues are addressed at all stages during the development and not just when adoption targets are not being met, commercial analytic solutions can be exploited to attain the anticipated value and more.
  • Modelling ‘smart’ and ‘lazy' thinking to influence decision-making Modelling ‘smart’ and ‘lazy' thinking to influence decision-making Dominic Tyer Recorded: Oct 4 2016 55 mins
    Traditional models of cognitive behaviour remain meaningful, but they can fail to deliver strong links between ‘smart’, cognitive-based factors of judgement and the decision-making associated with actual behaviour change.

    In contrast, behavioural economics accounts for the ‘lazy’ judgments and thoughts that occur at an automatic level, but can over-weight the prevalence of such behaviour.

    On October 4 Cello Health Insight, in association with PMGroup, will host a free webinar on applying adaptive and integrated behavioural models to qualitative enquiry.

    It will look at how to achieve a better understanding of what drives therapeutic decision-making and how medical marketing, digital and PR initiatives can change future behaviours in favour of achieving target sales.
  • Strengthening market access deliverables by harnessing the patient journey Strengthening market access deliverables by harnessing the patient journey Dominic Tyer Recorded: Sep 14 2016 58 mins
    In today’s multi-stakeholder environment, pharma companies need to coordinate their stakeholder interactions between functions to ensure consistency of message and efficiency of cost.

    The patient journey can be at the centre of this drive by shaping an aligned communication on ‘value’.

    On 14 September Executive Insight, in association with PMGroup, will host a free webinar about how to leverage the patient journey to strengthen market access deliverables.

    It will investigate how to develop a common value story, what such a framework should look like and the role of cross-functional working when it comes to putting these ideas into practice.
  • The value of early asset development and commercialisation The value of early asset development and commercialisation Dominic Tyer Recorded: Jul 13 2016 56 mins
    Linking the clinical benefit of a product to a real-world benefit that markets care about, insurers will pay for and that will improve patients’ lives is critical for pipeline assets to succeed.

    On July 13 Cello Health, in association with PMGroup, will host a free webinar on the value of early asset development and commercialisation.

    It will follow the asset development journey, defining value from both a financial and clinical perspective, and look at the variables with which companies must contend in order to optimize a product’s prospects.
  • Developing medical education that advances patient outcomes Developing medical education that advances patient outcomes Dominic Tyer Recorded: Jun 30 2016 56 mins
    As pressure mounts on the pharmaceutical industry to demonstrate a tangible and positive impact on patients’ lives, understanding barriers to specific clinician behaviours is key to achieving measurable change in clinical practice and advancing patient outcomes.

    Medical education has the potential to affect a significant number of healthcare professionals’ (HCPs) clinical practice and so improve patients’ outcomes.

    Nonetheless, achieving these goals requires medical education to move beyond didactic message delivery - that only improves HCPs’ awareness - to using many multi-channel educational interventions to drive real behaviour change.

    In this webinar, Lucid will discuss why, as an industry, we should all be moving beyond our internal goals to think about how we can improve patient outcomes with all our programmes and share a process for creating measurable improvements.
  • Customer engagement design in pharma Customer engagement design in pharma Dominic Tyer Recorded: May 19 2016 56 mins
    In recent years pharma has slowly been realising the importance of customer experience and the fact that the commercial model that served it so well for the past 30 years might not be the right one for the future.

    But continued ‘evolution’ is no longer acceptable - a more revolutionary approach to customer engagement design that makes it easy for front line employees to engage andmakes it relevant and unique for the customer is needed before it is too late.

    On 19 May EY, in association with PMGroup, will host a free webinar on customer engagement design in pharma and time to move beyond the rhetoric, and I would like to invite you to register for it - either to watch it live on the day or for access to a recorded version.
  • Rare diseases: Regulatory and reimbursement submissions, the challenges Rare diseases: Regulatory and reimbursement submissions, the challenges Dominic Tyer Recorded: Mar 22 2016 74 mins
    Companies developing new rare disease treatments face several unique challenges when it comes to their regulatory and reimbursement submissions.

    One of the most pressing of these is the paucity of information on patient populations, disease progression and appropriate Clinical Outcome Assessments (COAs), which form an important part of assessing signs and symptoms of rare diseases and treatment response.